2C). == Subcellular distribution of human DAT and NET variants == Immunoblots of COS-7 cells transiently expressing FL hDAT revealed both 8085 kDa and 50 kDa bands in the total extract (Determine 3A). the Mouse monoclonal to IL-2 C-terminus of DAT labeled the variant but not FL DAT, when cells were not treated with Triton for permeabilization, suggesting the C-terminus of the variant to be located extracellulary. Co-expression of the FL isoform with the truncated isoform in COS-7 cells resulted in a reduced uptake of substrates, indicating a Lomitapide mesylate dominant negative effect of the variant. Furthermore, an immunoprecipitation assay revealed physical interaction between the FL and truncated isoforms. == Conclusions/Significance == The unique expression and function and the proposed membrane topology of the variants suggest the importance of isoforms of catecholamine transporters in monoaminergic signaling in the brain and peripheral tissues. == Introduction == Neurotransmitter transporters accumulate extracellular neurotransmitters released from nerve terminals to maintain synaptic clearance, thereby controlling the fine-tuning of neurotransmission[1]. Psychostimulants including cocaine and amphetamines exert their pharmacological effects by acting on monoamine neurotransmitter transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT)[2],[3]. DAT, NET, and SERT, along with transporters for GABA and glycine, are Na+- and Cl-dependent neurotransmitter transporters, having 12 hydrophobic transmembrane domains (TMDs) and intracellular N- and C-termini[4],[5]. Lomitapide mesylate There is increasing evidence that neurotransmitter transporters are not constitutively expressed at nerve endings, Lomitapide mesylate but rather, dynamically regulated by various cellular mechanisms. One such mechanism could be option splicing. We as well as others have reported various NET splice variants in different species including rats, cows and humans[observe ref. 6 for review]. However, there is no evidence for the occurrence Lomitapide mesylate of DAT isoforms produced by option splicing. Recently, Miller et al.[7]reported a variant of monkey NET, generated by alternative splicing in the region encoded by exon 6. They reported that when expressed in COS-7 cells, the variant failed to reveal any transport activity. However, few details were given about the structure, function and expression of this mutant. Skipping exon 6 causes the nucleotide sequence to shift in frame, resulting in evasion of nonsense mediated decay (NMD) operating to eliminate aberrant RNA[8]. This isoform of monkey NET was predicted to lack the 5th TMD, leading to a potentially unique membrane topology. Recently, Yamashita et al.[9]elucidated the structure of a leucine transporter (LeuT), a bacterial homologue of the Na+- and Cl-dependent neurotransmitter transporters, using X-ray crystallography. These results confirmed the previously predicted 12 TMD structure, and provided new Lomitapide mesylate structural details. Furthermore, they suggested the dimerization of LeuT, with the 9th and 12th TMDs interacting[9]. A similar conclusion was reached for mammalian Na+- and Cl-dependent neurotransmitter transporters including DAT based on biochemical and molecular biological evidence[10]. We also reported that variants of rat NET produced by option splicing in the C-terminal region had a dominant negative effect on the functional expression of not only wild-type NET but also wild-type DAT[11]. Furthermore, Hahn et al.[12]recently demonstrated that a mutation in the human NET gene associated with orthostatic intolerance disrupted the surface expression of mutant and wild-type transporters, resulting from oligomerization as a potential mechanism of the dominant negative effect. Given these results, it is hard to speculate around the structure of the isoform missing the 5th TMD, and how splice variants missing exon 6 might exhibit a dominant unfavorable effect via conversation with wild-type DAT. We initially recognized isoforms of human NET (hNET) and DAT (hDAT) as counterparts of the monkey NET variant missing exon 6, in various tissues, since both DAT and NET are known to exist not only in the central nervous system but also in peripheral tissues, e.g. lymphocytes and gut for DAT[13],[14]and placenta for NET[15]. Thus, we further explored the mechanism of the functional expression of the novel hDAT and hNET isoforms. The current study demonstrated the unique expression and function and proposed a membrane topology of the hDAT and/or hNET variants that might contribute to our understanding of the importance of option splicing for monoamine neurotransmitter transporters. == Results == == Identification and characterization of variants of human catecholamine transporters == The screening of hNET cDNAs by RT-PCR in SK-N-SH cells[16]resulted in the identification of additional hNET variants, one of which lacked the region encoded by exon 6. We designated this clone hNETEX6. Since a monkey NET variant missing exon 6 has been reported, we explored the possible occurrence of counterparts among hDAT and hNET. An initial search of the EST database identified human NET but not DAT transcripts, which.